STRC LNP Cochlear Tropism Literature Scan — what’s actually achievable for OHC delivery
Question
STRC mRNA-LNP Strategy B Full-Length models three OHC-tropism scenarios for the LNP carrier — untargeted (0.8%), cochlear-tropic (5%), OHC-targeted (20%). What does the published literature actually report for cochlear LNP delivery, and where on this gate-line do current technologies sit? The “20%/50% gate” is aspirational unless backed by data. This scan asks: is 5% achievable today, is 20% achievable with known technology, is 50% science-fiction?
Method
Web-only scan, 2026-04-22. Targeted queries for “LNP/lipid nanoparticle cochlea hair cell transfection efficiency”, “SORT LNP inner ear”, “round window mRNA LNP”, “A666 prestin peptide nanoparticle”, “intracochlear LNP mRNA”. Triaged for quantitative OHC% with mRNA payload as the strict gate; counted peptide-targeted non-mRNA work as adjacent evidence.
Result — quantitative landscape (2018–2025)
| Formulation | Cargo | Route | Species | OHC% reported | Notes |
|---|---|---|---|---|---|
| ssPalm LNP (neutral) | BDNF mRNA | Round window niche | Guinea pig | not quantified for OHCs | Nazari et al. 2020 (Exp Brain Res) — SGN protection demonstrated; OHC uptake not reported. The only directly relevant LNP-mRNA cochlear paper found. |
| PEG-PLA NP + A666 prestin peptide | Dexamethasone | Round window | Guinea pig | not quantified (OHC-preserving therapeutic effect) | Wang et al. 2018 (Int J Nanomed, PMC6241721) — A666 (CLEPRWGFGWWLH) binds prestin extracellular loop; cisplatin-protective in OHCs at 4/8/16 kHz; ~83 nm particle. Drug payload, not mRNA — but proves OHC targeting concept. |
| PEGylated liposomes + prestin-binding peptide | TdTomato + carboxyfluorescein dye | Intratympanic | Mouse | qualitative — “expressed in OHCs” | Surovtseva et al. 2012 — early proof of OHC localisation with prestin-targeted liposomes. |
| Polymersome + prestin peptide | (proof of concept) | Intratympanic | Mouse | not quantified | 2012, prestin-peptide polymersomes reach OHC. |
| PAMAM dendrimer | siRNA | Intratympanic | Mouse | <10% (qualitative) | 2012, low efficiency, requires improvements. |
| AAV-Anc80L65 (reference) | OTOF cDNA | Round window | Mouse, NHP, Human | 60–100% (IHC-dominant by tropism) | Clinical OTOF trials, 2023–2025. AAV is the gold standard. |
| AAV-PHP.eB (reference) | reporter | Round window | Mouse | >95% hair cell transduction | Brain-evolved capsid; secondary literature. |
| SORT LNP (Siegwart group) | mRNA | IV | Mouse | n/a — liver/lung/spleen only | No inner ear publications. SORT chemistry has not been applied to cochlea. |
| AI-designed/LANTERN/optimized LNPs (2025) | mRNA | various | various | n/a for cochlea | Field is rapidly designing organ-tropic LNPs (brain, lung, lymph), but cochlea is not on the published target list. |
Interpretation against Strategy B’s three gates
0.8% (untargeted LNP — Strategy B “infeasible” baseline)
- Plausible. Untargeted ionizable-lipid LNPs delivered intracochlearly diffuse poorly; published data on systemic LNPs reaching the cochlea is essentially zero (LNPs hit liver and don’t cross the blood-labyrinth barrier).
- For Strategy B this scenario is correctly modelled as infeasible for cochlea-mean ≥ 1× WT in Misha.
5% (cochlear-tropic LNP — Strategy B “marginal therapeutic” gate)
- Achievable in principle with prestin-peptide conjugation (A666 chemistry from Wang et al. 2018, swapped from PEG-PLA dexamethasone NP onto an ionizable-lipid LNP-mRNA). The targeting moiety is published; the LNP-mRNA chassis is published; the hybrid hasn’t been done.
- Engineering risk: A666 was characterised on PEG-PLA, not on ionizable-lipid LNPs. Surface chemistry differs (PEG-DMG vs PEG-PLA presentation, ionizable lipid pKa interactions). Maintaining peptide presentation at endosomal pH change is non-trivial.
- Realistic best-in-class today, with ~12-18 months of development. Strategy B’s 5% scenario is plausible-but-unbuilt.
20% (OHC-targeted LNP — Strategy B “favourable” gate)
- Aspirational. Requires either (a) a SORT-style cochlea-tropic ionizable lipid (no published example), or (b) much higher A666-peptide density per LNP than has been demonstrated, or (c) round-window pretreatment to permeabilise the membrane (sodium caprate, junctional modulation per Tachibana et al. 2021) combined with peptide targeting.
- No published LNP-mRNA work hits 20% OHC tropism. Closest precedent: AAV-PHP.eB at >95% but that’s a different vector class entirely.
- Realistic best-case with directed development = 2-4 years out at 20% OHC, conditional on prestin-peptide LNP optimisation + RWM pretreatment. Not a 12-month gate.
50% (Strategy B’s high-rescue ceiling)
- Science-fiction with current LNP chemistry. AAV territory only.
What this means for Strategy B’s tier
The model in STRC mRNA-LNP Strategy B Full-Length showed that for Misha at 5% cochlear tropism, Q3W × 100K mol/pulse reaches cochlea-mean 2.18× WT — therapeutic. That clinical claim is not contradicted by this scan, but it depends on a peptide-conjugated LNP that has not been published with mRNA payload. The 20% scenario in the model is aspirational not buildable today — should be flagged as “research target” not “near-term clinical”.
The Delivery axis score in STRC Hypothesis Ranking is currently 2/5 for Strategy B. This scan says: 2/5 is correct. It is not 3/5 until a prestin-targeted LNP-mRNA cochlear paper is published. Mini-STRC AAV remains the dominant paternal-allele branch on delivery score (5/5) because AAV-Anc80L65 hits the cochlea today at 60-100%.
Concrete next steps
- Track: any peptide-conjugated LNP-mRNA cochlear publication. Set a journal alert on prestin + LNP keywords.
- Compute: extend the Strategy B model with a 1-3% OHC tropism row (the realistic “untargeted-but-intracochlear” scenario) — currently the model jumps from 0.8% systemic to 5% peptide-targeted with no intermediate.
- Compute: ER/UPR ceiling — Strategy B’s “no Hill ceiling, dose-linear” assumption breaks somewhere; literature on STRC overexpression toxicity in OHCs would constrain the safe upper dose. Likely a 3-5× WT soft ceiling per Lu et al. type studies on hair-cell protein overexpression.
- Talk: Jeffrey Holt is a key contact who would know which non-AAV LNP groups are working on cochlea — worth asking explicitly in the next reply.
Limitations
- Web-only scan, 2026-04-22; no PubMed comprehensive search via Entrez API. A full E-utility query (
("lipid nanoparticle"[tiab] OR "LNP"[tiab]) AND ("cochlea"[tiab] OR "hair cell"[tiab])) would surface more hits, especially older Japanese/Chinese groups. - Several recent reviews failed to fetch (403 paywall errors on Springer and ScienceDirect). Numbers extracted are from open-access PMC, abstracts, and search snippets only.
- Quantitative OHC% values for non-mRNA LNPs (dexamethasone, dye-loaded) were not extracted — the search prioritised mRNA payload to match Strategy B’s clinical question.
- Industry programs (ReCode, Tessera Therapeutics, Generation Bio) may have unpublished cochlear LNP programs not visible in this scan.
Connections
[part-of]STRC mRNA-LNP Strategy B Full-Length- STRC mRNA Therapy Hypothesis (Strategy A — same delivery layer constraint)
[see-also]STRC Mini-STRC Single-Vector Hypothesis (AAV alternative on the delivery layer)[see-also]STRC Anti-AAV Immune Response Model (the constraint that motivated mRNA-LNP as re-dosable alternative)[see-also]STRC Hypothesis Ranking- Jeffrey Holt (potential contact for non-public cochlear LNP groups)
[applies]Misha — cochlea-mean rescue depends on which tropism row the model lands on
Ranking delta
- STRC mRNA-LNP Strategy B Full-Length: no tier change (stays S). Evidence depth +1 on the delivery axis: confirms Delivery 2/5 score is correct. The 5% cochlear-tropic scenario is plausible-but-unbuilt (engineering risk on prestin-peptide LNP-mRNA hybrid); the 20% scenario is aspirational not near-term-buildable; the 50% scenario is science-fiction with current LNP chemistry. Misha-fit (5) and Mechanism (3) unchanged. Next step in the ranking table updated from “cochlear LNP tropism literature scan (20%/50% gate)” → “add 1-3% OHC tropism row + ER/UPR soft ceiling to Strategy B model; ask Holt for unpublished cochlear LNP program leads”.
- STRC mRNA Therapy Hypothesis (Strategy A): no change. Same delivery-layer constraint applies; Strategy A’s Misha-fit is already 2/5 because of the deletion-substrate-absence problem, not the delivery problem.
- STRC Mini-STRC Single-Vector Hypothesis: no change. AAV-Anc80L65 60-100% transduction (clinical OTOF trials) confirms Delivery 5/5 is correct and is the dominant paternal-allele delivery option until peptide-LNP-mRNA matures. Mini-STRC remains the strongest paternal-allele branch on delivery grounds.
- All other S/A/B/C tier hypotheses: no change.